Sumukadas Deepa, McMurdo Marion E T, Mangoni Arduino A, Guthrie Bruce
Ageing and Health, Division of Cardiovascular and Diabetes Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK.
Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Flinders Drive, Bedford Park, SA 5042, Australia.
Age Ageing. 2014 Jul;43(4):515-21. doi: 10.1093/ageing/aft199. Epub 2013 Dec 10.
in older people, medications with anticholinergic (antimuscarinic) effects are associated with adverse clinical outcomes, the risk increasing with increasing anticholinergic exposure. Many anticholinergics are recognised as potentially inappropriate and efforts to reduce prescription have been ongoing. We examined temporal trends of anticholinergic prescription and exposure in older people.
: anonymised data on all prescribed medication dispensed to people ≥65 years in Tayside, Scotland were obtained for the years 1995 (n = 67,608) and 2010 (n = 73,465). The Anticholinergic Risk Scale (ARS) was adapted (mARS) to include newer medications and medications identified in other scales as having moderate to strong anticholinergic activity. An individual's mARS score was the sum of scores for individual medications. Differences in prescription of anticholinergic medications and mARS scores between 1995 and 2010 were examined.
: a significantly higher proportion of older people received any anticholinergic medication in 2010 compared with 1995 (23.7 versus 20.7%; P < 0.001). High anticholinergic exposure (mARS scores ≥3) was seen in 7.3% in 1995 and 9.9% in 2010 (P < 0.001). Prescription of individual anticholinergic medication was small-only three medications were prescribed to >2% of people. The risk of high anticholinergic exposure increased in those with polypharmacy, social deprivation, those living in care homes and women.
: despite increasing evidence of adverse outcomes, the proportion of older people prescribed anticholinergic medications and the proportion with a high anticholinergic exposure has increased between 1995 and 2010. Prescription of individual drug is small so cumulative anticholinergic scores may help future efforts to reduce anticholinergic prescription in older people.
在老年人中,具有抗胆碱能(抗毒蕈碱)作用的药物与不良临床结局相关,且抗胆碱能暴露增加,风险也随之增加。许多抗胆碱能药物被认为可能不适当,减少其处方的努力一直在进行。我们研究了老年人抗胆碱能药物处方及暴露的时间趋势。
获取了1995年(n = 67608)和2010年(n = 73465)苏格兰泰赛德地区所有给65岁及以上人群配给的处方药物的匿名数据。对抗胆碱能风险量表(ARS)进行了调整(mARS),以纳入更新的药物以及在其他量表中被确定具有中度至强抗胆碱能活性的药物。个体的mARS分数为各药物分数之和。研究了1995年至2010年抗胆碱能药物处方和mARS分数的差异。
与1995年相比,2010年接受任何抗胆碱能药物治疗的老年人比例显著更高(23.7%对20.7%;P < 0.001)。1995年7.3%的老年人出现高抗胆碱能暴露(mARS分数≥3),2010年为9.9%(P < 0.001)。个体抗胆碱能药物的处方量很小,只有三种药物的处方量超过了2%的人群。多重用药者、社会贫困者、住在养老院的人和女性中高抗胆碱能暴露的风险增加。
尽管有越来越多的证据表明存在不良结局,但1995年至2010年间,开具抗胆碱能药物的老年人比例以及高抗胆碱能暴露的比例有所增加。个体药物的处方量很小,因此累积抗胆碱能分数可能有助于未来减少老年人抗胆碱能药物处方的努力。